1. Bioptigen Awarded $458,000 from North Carolina Biotechnology Center to Advance Intrasurgical OCT System Development

    Bioptigen Awarded $458,000 from North Carolina Biotechnology Center to Advance Intrasurgical OCT System Development

    Novel ophthalmic imaging tool would enable microscopic 3D surgical visualizations

    Bioptigen announced today that it has been awarded a Strategic Growth Loan from the North Carolina Biotechnology Center totaling $458,000 to support development of the company’s Intrasurgical OCT imaging system. Optical Coherence Tomography or ‘OCT’ is a form of highresolution imaging that has been compared to ultrasound imaging, though OCT uses light rather than sound to create the images.

    Bioptigen’s EnFocusTM Intrasurgical OCT system will provide 3D visualization simultaneous with and coregistered to images from surgical ophthalmic microscopes. Bioptigen is known globally for its FDA-cleared handheld OCT system for pediatric imaging, and for providing industry leading OCT imaging to the ophthalmology research community. The company’s existing OCT technology has been the featured equipment in the PIONEER intrasurgical OCT imaging study at the Cleveland Clinic.

    NCBiotech awarded the loan to Bioptigen specifically to support clinical validation of a new microscope integrated OCT system targeting cataract and advanced cornea surgeries. More than 20 million cataract surgeries are performed each year. The addition of depth resolved intrasurgical imaging with OCT is motivated by reducing the need for post-surgical follow up procedures, enabling new classes of precision surgery with higher success rates, and improving visual outcomes for patients.

    “We are very pleased to receive this award from the NCBiotech Center,” said Bioptigen CEO Dr. Eric Buckland. “The work advanced under this loan will bring ophthalmic surgeons a step closer to realizing the full potential of intrasurgical OCT.”

    Besides the NCBiotech Award, Bioptigen has recently received a Fast Track SBIR grant from the National Eye Institute for development of Intrasurgical OCT.

     

    Figure 1: Bioptigen Envisu SDOCT System in use during ophthalmic surgery

     

    Figure 2: Bioptigen Envisu Microscope Mounted SDOCT System in use during ophthalmic surgery

    Caution: Bioptigen’s EnFocus SDOCT is an investigational device, limited by United States law to investigational use. The device is not cleared by the FDA to be marketed, sold, or distributed within the United States.

    Bioptigen Inc. is an innovative medical technology company located in Morrisville, NC. Bioptigen’s OCT imaging devices are sold to pediatric and surgical ophthalmology clinics and hospitals, and academic ophthalmology research centers globally. Learn more about Bioptigen and its technologies at www.bioptigen.com.

    The North Carolina Biotechnology Center is a private, non-profit corporation supported by the N.C. General Assembly. Its mission is to provide long-term economic and societal benefits to North Carolina by supporting biotechnology research, business, education and strategic policy statewide. Learn more about the NC Biotech Center at www.NCBiotech.org

    Login to comment.

  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. Quotes

    1. We are very pleased to receive this award from the NCBiotech Center... The work advanced under this loan will bring ophthalmic surgeons a step closer to realizing the full potential of intrasurgical OCT.
  3. Topics Mentioned

  4. Authors